A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
Status: Recruiting
Location: See all (9) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:
• Received at least 1 dose of treatment with vonsetamig in study R5459-RT-1944 \[NCT05092347\].
• Received after acceptable crossmatching, a kidney transplant while enrolled in study R5459-RT-1944
• Willing and able to comply with clinic visits and study-related procedures
• Provide informed consent signed by study patient or legally acceptable representative
Locations
United States
California
Cedars-Sinai Medical Center
RECRUITING
Los Angeles
University of California Irvine
RECRUITING
Orange
Connie Frank Transplant Center at UCSF
RECRUITING
San Francisco
Connecticut
Yale University of Medicine
RECRUITING
New Haven
Illinois
Comprehensive Transplant Center
RECRUITING
Chicago
Maryland
John Hopkins Hospital
RECRUITING
Baltimore
Minnesota
University of Minnesota
RECRUITING
Minneapolis
New York
New York University Langone Health
RECRUITING
New York
Pennsylvania
Penn Transplant Institute
RECRUITING
Philadelphia
Contact Information
Primary
Clinical Trials Administrator
clinicaltrials@regeneron.com
844-734-6643
Time Frame
Start Date: 2023-10-19
Estimated Completion Date: 2027-12-24
Participants
Target number of participants: 20
Treatments
Vonsetamig in study R5459-RT-1944
Received a kidney transplant and were administered vonsetamig in study R5459-RT-1944 \[NCT05092347\].
Related Therapeutic Areas
Sponsors
Leads: Regeneron Pharmaceuticals